SEMI–MATURE DENDRITIC CELLS AS A POTENTIAL BASIS FOR THE INDUCTION OF ANTI–TUMOR RESPONSE IN PATIENTS WITH MALIGNANT GLIOMAS

Abstract. The comparative analysis of phenotypical and functional features of dendritic cells (DCs), generated in presence of GM–CSF and IFNα from blood monocytes of patients with malignant gliomas (MG) and healthy donors, was carried out in this research. The potential value of the DC–based immunotherapy in the induction of anti–tumor response in patients with MG was also examined. Our results show that within generated DCs of healthy donors 90 and 52% cells expressed correspondingly HLA–DR and CD86, only 17–18% cells were CD14+monocytes, whereas 38% cells exhibited the phenotype of mature CD83+ dendritic cells. The both monocyte conditioned medium (MCM, 30% v/v) and Leukinferon® (250 IU of IFNα) were comparably efficient as maturation–induced stimuli. Despite monocyte’s disturbances in malignant gliomas, the analogous population of DCs was efficiently generated in all examined patients with MG. However, the percentage of mature CD83+DCs was significantly decreased compared to that in healthy donors (24 vs 38%), and these data strongly suggest the delay maturation of DCs in MG. Nevertheless the patient’s DCs showed the allostimulatory activity, comparable with healthy donor’s DCs, and 52–62% cells maintained the ability for the receptor–dependent en–docytosis. Moreover, the patient’s DCs effectively presented bacterial and tumor–associated antigens (TAA). Immunotherapy with autologous DCs allowed to induce the TAA–specific immune reactions, both in skin test in vivo and in vitro, in 50% patients with MG. (Med. Immunol., 2005, vol.7, № 4, pp. 365–374)

1. Лозовой В.П., Кожевников В.С. Методы оценки клеточных эффекторных функций гиперчувствительности замедленного типа // Методические рекомендации. – Москва, 1990. – С.1–10.

2. Останин А.А., Центнер М.И., Хонина Н.А., Леплина О.Ю., Шевела Е.Я., Никонов С.Д., Ступак В.В., Черных Е.Р. Антигенспецифическая иммунотерапия в комплексном лечении больных со злокачественными опухолями головного мозга // Вопр. онкологии. — 2003. — Т. 49, № 2. — С. 170–175.

3. Хонина Н.А., Центнер М.И., Леплина О.Ю., Тихонова М.А., Ступак В.В., Никонов С.Д., Черных Е.Р., Останин А.А. Характеристика и механизмы иммунных нарушений у больных со злокачественными опухолями головного мозга // Вопр. онкологии. — 2002. — Т. 48, № 2. — С. 196–201.

4. Черных Е.Р., Леплина О.Ю., Останин А.А., Никонов С.Д., Ступак В.В., Козлов Ю.П. Способ иммунотерапии злокачественных опухолей головного мозга // Заявка на изобретение № 2004100550/14 (00155) приоритет от 05.01.2004 г.

5. Черных Е.Р., Ступак В.В., Центнер М. И., Хонина Н. А., Леплина О. Ю., Тихонова М.А., Никонов С. Д., Останин А. А. Комбинированная иммунотерапия в лечении злокачественных опухолей головного мозга // Мед. иммунология. — 2002. — Т. 4, № 4/5. — С.583–592.

6. Adams M., Navaba H., Jasani B., Man S., Fiander A., Evans A.S., Donninger C., Mason M. D. Dendritic cell based therapy for cervical cancer – use of DC pulsed with tumour lysate and matured with a novel synthetic clinically non–toxic double stranded RNA analogue poly // Vaccine.– 2003. – Vol.21. – P.787–790.

7. Akasaki Y., Kikuchi T., Homma S. Antitumor effect of immunizations with fusions of dendritic and glioma cells in a mouse brain tumor model // J. Immunother. — 2001.–Vol. 24. — P. 106–113.

8. Asavaroengchai W., Kotera Y., Mule J.J. Tumor lysate–pulsed dendritic cells can elicit an effective antitumor immune response during early lymphoid recovery // Proc. Natl. Acad. Sci. USA. 2002. – Vol. 99. – P. 931–936.

9. Baar J. Clinical applications of dendritic cell cancer vaccines // Oncologist. – 1999. – Vol. 4. – P. 140–144.

10. Bjork P. Development of dendritic cells and their use in tumor therapy // Clin. Immunol.– 1999. – Vol. 92, N. 2. – P. 119–127.

11. Fong L., Engleman E.G. Dendritic cells in cancer immunotherapy // Annu. Rev. Immunol. — 2000.Vol. 18. — P. 245–273.

12. Kikuchi T., Akasaki Y., Irie M. Results of a phase I clinical trial of vaccination of glioma patients with fusions of dendritic and glioma cells //Cancer Immunol Immunother. — 2001. – Vol.50.– P.337–344.

13. Liau L.M., Black K.L., Prins R.M. Treatment of intracranial gliomas with bone–marrow–derived dendritic cells pulsed with tumor antigens. // J.Neurosurg.–1999.–Vol.90.–P.1115–1124.

14. Lipcomb M., Masten B.J. Dendritic cells – immune regulators in health and disease // Physiol. Rev. – 2002. – Vol.82. – P.97–130.

15. Mcllroy D., Gregoire M. Optimizing dendritic cell–based anticancer immunotherapy – maturation state does have clinical impact // Cancer Immunol. Immunother. – 2003. — Vol. 52. – P. 583–591.

16. Murphy G., Tjoa B., Simmons S., Jarisch J., Bowes V., Ragde H., Elgamal A., Kenny G., Cobb O., Ireton R., Troychak M., Salgaller M., Boynton A. Infusion of dendritic cells pulsed with HLA–A2–spesific prostate–specific membrane antigen peptides – a phase II prostate cancer vaccine trial involving patients with hormone–refractory metastatic disease // Prostate. — 1999. – Vol. 38. – P. 73–78.

17. Orada I., Tahara I., Shurin M., Attanucci J., Giezeman –Smits K., Fellows W., Lotze M., Chambers W., Bozik M. Bone marrow–derived dendritic cells pulsed with a tumor–specific peptide el icit effective anti–tumor immunity against intracranial neoplasms // J. Neurooncol. — 1998. – Vol. 38. – P. 233239.

18. Parlato S., Santini S., Lapenta C., Di Pucchio T., Logozzi M., Spada M., Giammarioly A., Malorni W., Fais S., Bellardelli F. Expression of CCR–7, MIP3b, and Th1 chemokines in type I IFN–induced monocyte–derived dendritic cells – importance for the rapid acquisition of potent migratory and functional activities // Blood. — 2001. – Vol.98. – P. 3022–3029.

19. Pickl W., Majdic O., Kohl P., Stockl J., Reidl E., Scheinecker C., Bello–Fernandez C., Knapp W. Molecular and functional characteristics of dendritic cells generated from highly purified CD 14 peripheral blood monocytes // J. Immunol. — 1996. – Vol. 157. – P. 3850–3859.

20. Piemonti L., Monti P., Allavena P., Leone B.E., Caputo A., Carlo V.D. Glucocorticoids increase the endocytic activity of human dendritic cells // Int. Immunol. – 2002. – Vol. 11.– N. 9. – P. 1519–1526.

21. Santini S., Lapenta C., Logozzi M., Parlato S., Spada M., Di Pucchio T., Bellardelli F. Type I Interferon as a powerful adjuvant for monocyte–derived dendritic cells development and activity in vitro and in HU–PBL–SCID mice // J. Exp. Med.– 2000.–Vol. 191. – P. 1777–1788.

22. Schuler–Thurner B., Schultz E., Berger T., Weinlich G., Ebner S., Woel P., Bender A., Feuerstain B., Fritsch P., Romani N., Schuler G. Rapid induction of tumor–specific type I T–helper cells in metastatic melanoma patients by vaccination with mature, cryopreserved, peptide–loaded monocyte–derived dendritic cells // J. Exp. Med.– 2002. — Vol. 195. – P. 1279–1288.

23. Steinman R.M., Dodhapkar M. Active immunization against cancer with dendritic cells: the near future // Int. J. Cancer. — 2001. — Vol. 94. — P. 459–473.

24. Thurner B., Roder C., Dieckmann D., Heuer M., Kruse M., Glaser A., Keikavoussi P., Kampgen E., Bender A., Schuler G. Generation of large numbers of fully mature and stable dendritic cells from leukapheresis products for clinical applications // J. Immunol. Meth. – 1999. – Vol. 223. – P. 1–15.

25. Valone F.H., Small E., MacKenzie M., Burch P., Lacy M., Peshwa M.V., Laus R. Dendritic cellbased treatment of cancer: closing in on a cellular therapy // Cancer J. — 2001. — Vol. 1/2. — P. 53–61.

26. Yamanaka R., Abe T., Yajima N., Tsuchiya N., Homma J., Kobayashi T., Narita M., Takahashi M., Tanaka R. Vaccination of recurrent glioma patientswith tumor lysate–pulsed dendritic cells elicits immune responses: results of a clinical phase I/II trial // Br. J. Cancer. — 2003. — Vol. 89. — P. 1172–1179.

27. Yamanaka R., Yajima N., Abe T., Tsuchiya N., Homma J., Narita M., Takahashi M., Tanaka R. Dendritic cell–based glioma immunotherapy // Int. J. Oncol . — 2003. — Vol. 23.–P. 5–15.

28. Yu J.S., Wheller C.J., Zelter P., Ying H., Finger D., Lee P.K., Yong W.H., Incardona F., Thompson R., Riedinger M., Zhang W., Prins R., Black K. Vaccination of malignant glioma patients with peptide–pulsed dendritic cells elicit systemic cytotoxity and intracranial T–cell infiltration // Cancer Res.2001.– Vol. 61. – P. 842–847.